Sthree Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
- Paid Up Capital ₹ 6.00 Cr
- Company Age 9 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -99.73%
- Profit Growth 100.29%
- Ebitda 99.97%
- Net Worth 0.01%
- Total Assets
About Sthree Pharmaceuticals
Sthree Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 August 2015 (Nine years and five months 29 days old ). Its registered office is in Kanchipuram, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 6.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Shanmugam Muthusamy, Ayyavu Rajavel, Duraisamy Sengottuvelu, and One other member serve as directors at the Company.
Company Details
-
Location
Kanchipuram, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24297TN2015PTC101802
-
Company No.
101802
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Aug 2015
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Sthree Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Muthusamy
|
Director | 06-Oct-2017 | Current |
Ayyavu Rajavel
|
Director | 06-Oct-2017 | Current |
|
Duraisamy Sengottuvelu
|
Director | 13-Aug-2015 | Current |
|
Jayanthy Shanmugam
|
Director | 06-Oct-2017 | Current |
Financial Performance of Sthree Pharmaceuticals.
Sthree Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 99.73% decrease. The company also saw a substantial improvement in profitability, with a 100.29% increase in profit. The company's net worth moved up by a moderate rise of 0.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sthree Pharmaceuticals?
In 2022, Sthree Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Saimirra Innopharm Private LimitedShanmugam Muthusamy and Ayyavu Rajavel are mutual person
-
Delvin Surgicals Private LimitedAyyavu Rajavel is a mutual person
-
Nuray Chemicals Private LimitedShanmugam Muthusamy and Ayyavu Rajavel are mutual person
-
Scitus Pharma Services Private LimitedShanmugam Muthusamy, Ayyavu Rajavel and 1 more are mutual person
-
Annamar Pharma LlpShanmugam Muthusamy, Duraisamy Sengottuvelu and 1 more are mutual person
-
Esjay Pharma Private Limited
Shanmugam Muthusamy and Ayyavu Rajavel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sthree Pharmaceuticals?
Unlock and access historical data on people associated with Sthree Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sthree Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sthree Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
